Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
David Trent TeacheyMeenakshi DevidasBrent L WoodZhiguo ChenRobert J HayashiMichelle L HermistonRobert D AnnettJ Hunter ArcherBarbara L AsselinKeith J AugustSteve Y ChoKimberly P DunsmoreBrian T FisherJason L FreedmanPaul J GalardyPaul Harker-MurrayTerzah M HortonAlok I JajuAllison LamYoav H MessingerRodney R MilesMaki OkadaSamir I PatelEric S SchaferTal SchechterNeelam SinghAmii C SteeleMaria Luisa SulisSarah L VargasStuart S WinterCharlotte WoodPatrick Zweidler-McKayCatherine M BollardMignon L LohStephen P HungerElizabeth A RaetzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse.
Keyphrases
- phase iii
- newly diagnosed
- clinical trial
- acute lymphoblastic leukemia
- open label
- phase ii
- double blind
- multiple myeloma
- diffuse large b cell lymphoma
- palliative care
- young adults
- placebo controlled
- allogeneic hematopoietic stem cell transplantation
- cardiac resynchronization therapy
- study protocol
- free survival
- randomized controlled trial
- acute myeloid leukemia
- left ventricular
- drug induced
- cell therapy
- replacement therapy